UNSPSC 51144603: Propentofylline

This classification denotes a neuroprotective agent with the molecular formula C15H22N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5RTA398U4H, chemically known as 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl-1h-purine-2,6-dione but more generally known as propentofylline, which bears US NIH Compound Identifier 4938. European Medicines Agency schedules Propentofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10102MIG.

UNSPSC 51144603 Propentofylline is a Commodity code that nominally designates a specific pharmaceutical compound, but recent state and local procurement activity under this code does not reflect propentofylline-specific buying. Instead, the three most recent opportunities tagged to this code solicit naloxone, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription program capabilities — a mismatch between the code's nominal scope and actual procurement activity. State and local governments are using this code to acquire a broad range of pharmaceutical products and services, including emergency opioid-reversal supplies, generic drug inventories for public health systems, and pharmacy benefit program infrastructure. Issuing bodies span county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances. The code shows no evidence of repeat buyers or concentrated activity among a small set of jurisdictions in the available records.

Geographic activity appears concentrated in the Southeast and Southwest, with recent solicitations from Seminole County, Florida (IFB for naloxone and drug deactivation systems, response due July 26, 2023), the Texas Health and Human Services Commission (RFI on direct-to-manufacturer prescriptions, posted April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating jurisdictions (RFP for generic pharmaceuticals and OTC products, response due March 26, 2026). The Seminole County IFB sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB, while the Minnesota cooperative issued an RFP for generic multi-source pharmaceuticals with pricing evaluations weighted 75 percent on price competitiveness and 25 percent combined on fixed pricing, administrative compliance, EDI capability, and administrative fee agreements. The Texas RFI represents earlier-stage market intelligence gathering ahead of formal competitive solicitation. The code's activity suggests fragmented, episodic demand across health systems and state pharmaceutical programs rather than sustained, high-volume procurement from a consolidated buyer base.